Edna F. Choo

3.5k citations

54 papers · 1.9k indexed · h-index 24

Pharmacology top 1%
- Pharmacogenetics and Drug Metabolism 12
- Drug-Induced Hepatotoxicity and Protection 5
Oncology top 5%
- Drug Transport and Resistance Mechanisms 9
Virology top 5%
Hematology top 5%
Molecular Biology top 10%
- Melanoma and MAPK Pathways 20
- PI3K/AKT/mTOR signaling in cancer 9
- Protein Kinase Regulation and GTPase Signaling 5
Pediatrics, Perinatology and Child Health
- Pharmacological Effects and Toxicity Studies 8
Computational Theory and Mathematics
- Computational Drug Discovery Methods 5

Co-authors: G. Wilkinson Richard B. Kim Alastair J.J. Wood Hitoshi Imamura Brenda F. Leake Jason Boggs Marcia Belvin Mark Merchant
Cited by: Pharmacology Oncology Virology
Journals: Cancer Research (5 papers)Clinical Cancer Research (2 papers)Journal of Medicinal Chemistry (1 paper)
Partner nations: United States Canada France

In The Last Decade

Edna F. Choo

53 papers receiving 1.9k citations

Peers

Countries citing papers authored by Edna F. Choo

Since Specialization

Citations

This map shows the geographic impact of Edna F. Choo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edna F. Choo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edna F. Choo more than expected).

Fields of papers citing papers by Edna F. Choo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edna F. Choo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edna F. Choo. The network helps show where Edna F. Choo may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Edna F. Choo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Edna F. Choo Line = papers co-authored together Edna F. Choo links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Bioactivation of α,β-Unsaturated Carboxylic Acids Through Acyl Glucuronidation Drug Metabolism and Disposition ·Teresa Mulder,Sudheer Bobba,Kevin M. Johnson,Jessica M. Grandner,Wei Wang,Chenghong Zhang,Jingwei Cai,Edna F. Choo,S. Cyrus Khojasteh,Donglu Zhang	2020	9
2	Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models Haematologica ·Raghuveer Singh Mali,Qi Zhang,RosaAnna DeFilippis,Antonio Cavazos,Vinitha M. Kuruvilla,Jayant Raman,Vidhi Mody,Edna F. Choo,Monique Dail,Neil P. Shah,Marina Konopleva,Deepak Sampath,Elisabeth A. Lasater	2020	97
3	Practical strategies when using a stable isotope labeled microtracer for absolute bioavailability assessment: A case study of a high oral dose clinical candidate GDC-0810 Journal of Pharmaceutical and Biomedical Analysis ·Buyun Chen,Pingping Lu,Dugan Freeman,Yang Gao,Edna F. Choo,Kevin DeMent,Scott Savage,Kelly Zhang,Dennis Milanwoski,Lichuan Liu,Brian Dean,Yuzhong Deng	2018	2
4	Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer Cancer Research ·Lingyan Jin,Jesse Garcia,Emily Chan,Cecile de la Cruz,Ehud Segal,Mark Merchant,Samir Kharbanda,Ryan Raisner,Peter M. Haverty,Zora Modrušan,Justin Q. Ly,Edna F. Choo,Susan Kaufman,Maureen H. Beresini,F. Anthony Romero,Steven Magnuson,Karen E. Gascoigne	2017	105
5	Absorption, metabolism and excretion of cobimetinib, an oral MEK inhibitor, in rats and dogs Xenobiotica ·Ryan Takahashi,Shuguang Ma,Qin Yue,Heasook Kim‐Kang,Yijun Yi,Justin Q. Ly,Jason Boggs,Alec Fettes,Andrew McClory,Yuzhong Deng,Cornelis E. C. A. Hop,S. Cyrus Khojasteh,Edna F. Choo	2016	7
6	A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth Cancer Research ·Ted Lau,Emily Chan,Marinella Callow,Jo Waaler,Jason Boggs,Robert A. Blake,Steven Magnuson,Amy Sambrone,Melissa M. Schutten,Ron Firestein,Ondřej Machoň,Vladimír Kořínek,Edna F. Choo,Dolores Diaz,Mark Merchant,Paul Polakis,Daniel D. Holsworth,Stefan Krauß,Mike Costa	2013	256
7	The Role of Lymphatic Transport on the Systemic Bioavailability of the Bcl-2 Protein Family Inhibitors Navitoclax (ABT-263) and ABT-199 Drug Metabolism and Disposition ·Edna F. Choo,Jason Boggs,Chunqiang Zhu,Joseph W. Lubach,Nathaniel D. Catron,Gary J. Jenkins,Andrew J. Souers,Richard Voorman	2013	50
8	Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts Breast Cancer Research and Treatment ·Inna Y. Gong,Wendy A. Teft,Justin Q. Ly,Yung‐Hsiang Chen,Bruno Alicke,Richard B. Kim,Edna F. Choo	2013	28
9	An Algorithm for Evaluating Potential Tissue Drug Distribution in Toxicology Studies from Readily Available Pharmacokinetic Parameters Journal of Pharmaceutical Sciences ·Patrick Poulin,Donna M. Dambach,Dylan H. Hartley,Kevin A. Ford,Frank‐Peter Theil,Eric B. Harstad,Jason Halladay,Edna F. Choo,Jason Boggs,Bianca M. Liederer,Brian Dean,Dolores Diaz	2013	9
10	Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response Clinical Cancer Research ·Harvey Wong,Edna F. Choo,Bruno Alicke,Xiao Ding,Hank La,Erin McNamara,Frank‐Peter Theil,Jay Tibbitts,Lori S. Friedman,Cornelis E. C. A. Hop,Stephen E. Gould	2012	96
11	Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor Clinical Cancer Research ·Harvey Wong,Laurent Vernillet,Amy Peterson,Joseph A. Ware,Lillian Lee,Jean‐François Martini,Peiwen Yu,Congfen Li,Geoffrey Del Rosario,Edna F. Choo,Klaus P. Hoeflich,Yongchang Shi,Blake T. Aftab,Ron Aoyama,Sanh Tan Lam,Marcia Belvin,John Prescott	2012	65
12	Pharmacokinetic drivers of toxicity for basic molecules: Strategy to lower pKa results in decreased tissue exposure and toxicity for a small molecule Met inhibitor Toxicology and Applied Pharmacology ·Dolores Diaz,Kevin A. Ford,Dylan P. Hartley,Eric B. Harstad,Gary Cain,Kirsten Achilles-Poon,Trung Van Nguyen,Jing Peng,Zhong Zheng,Mark Merchant,Daniel P. Sutherlin,John J. Gaudino,Robert Kaus,Sock C. Lewin-Koh,Edna F. Choo,Bianca M. Liederer,Donna M. Dambach	2012	22
13	PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts Cancer Chemotherapy and Pharmacology ·Edna F. Choo,Chee M. Ng,Leanne Berry,Marcia Belvin,Nicholas Lewin‐Koh,Mark Merchant,Laurent Salphati	2012	26
14	Overview of SLC22A and SLCO Families of Drug Uptake Transporters in the Context of Cancer Treatments Current Drug Metabolism ·Murray J. Cutler,Edna F. Choo	2011	23
15	Preclinical assessment of novel BRAF inhibitors: integrating pharmacokinetic-pharmacodynamic modelling in the drug discovery process Xenobiotica ·Edna F. Choo,Bruno Alicke,Jason Boggs,Vikki Dinkel,Stephen E. Gould,Jonas Grina,Kristina West,Kapil Menghrajani,Yingqing Ran,Joachim Rudolph,Steve Wenglowsky	2011	5
16	Preclinical disposition and pharmacokinetics-pharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor Xenobiotica ·Edna F. Choo,Marcia Belvin,Jocelyn Chan,Klaus P. Hoeflich,Christine Orr,Kirk Robarge,Xiaoye Yang,Mark Zak,Jason Boggs	2010	17
17	Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression Cancer Research ·Klaus P. Hoeflich,Sylvia Herter,Janet Tien,Leo Lap-Yan Wong,Leanne Berry,Jocelyn Chan,Carol O’Brien,Zora Modrušan,Somasekar Seshagiri,Mark R. Lackner,Howard M. Stern,Edna F. Choo,Lesley Murray,Lori S. Friedman,Marcia Belvin	2009	144
18	Differential in Vivo Sensitivity to Inhibition of P-glycoprotein Located in Lymphocytes, Testes, and the Blood-Brain Barrier Journal of Pharmacology and Experimental Therapeutics ·Edna F. Choo,Daniel Kurnik,Mordechai Muszkat,Tadashi Ohkubo,Sheila Shay,James N. Higginbotham,Hartmut Glaeser,Richard B. Kim,Alastair J.J. Wood,G. Wilkinson	2006	64
19	Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species Xenobiotica ·Amit S. Kalgutkar,Edna F. Choo,Tim Taylor,Anthony Marfat	2004	13
20	In vivo inhibition of human CYP1A2 activity by oltipraz Cancer Chemotherapy and Pharmacology ·G. Sofowora,Edna F. Choo,Gail Mayo,Yu Shyr,G. Wilkinson	2001	27

About Edna F. Choo

Edna F. Choo is a scholar working on Pharmacology, Oncology and Molecular Biology, having authored 54 papers that have together received 1.9k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (20 papers), Pharmacogenetics and Drug Metabolism (12 papers), PI3K/AKT/mTOR signaling in cancer (9 papers), Drug Transport and Resistance Mechanisms (9 papers), Pharmacological Effects and Toxicity Studies (8 papers), Protein Kinase Regulation and GTPase Signaling (5 papers), Computational Drug Discovery Methods (5 papers) and Drug-Induced Hepatotoxicity and Protection (5 papers). The work is most often cited by research in Pharmacology (286 citations), Oncology (797 citations) and Virology (100 citations). Edna F. Choo has collaborated with scholars based in United States, Canada and France. Frequent co-authors include G. Wilkinson, Richard B. Kim, Alastair J.J. Wood, Hitoshi Imamura, Brenda F. Leake, Jason Boggs, Marcia Belvin, Mark Merchant, Justin Q. Ly and Klaus P. Hoeflich. Their work appears in journals such as Cancer Research, Clinical Cancer Research and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact